Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Neurol
Autors principals: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2018
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars